Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Int J Biochem Cell Biol. 2021 Jul;136:106002. doi: 10.1016/j.biocel.2021.106002. Epub 2021 May 4.
Preclinical data suggest that head and neck cancer is an intrinsically immunosuppressive disease with abnormal inflammatory components in the tumor microenvironment. The development of immune checkpoint inhibitors, which are monoclonal antibodies capable of inhibiting immune suppressive signals to prime anticancer immunity, has revolutionized the therapeutic landscape in recurrent/metastatic head and neck cancer. However, patients with head and neck cancer present primary resistance to immunotherapy. Many ongoing trials include combinations of immunotherapy with different therapeutic interventions, aiming to improve response rates and overall survival. As novel therapy strategies are leveraged, the significance of immunotherapy in recurrent/metastatic head and neck cancer continues to be revealed. This review aims to summarize combinational immunotherapy in head and neck cancer.
临床前数据表明，头颈部癌症是一种固有免疫抑制性疾病，肿瘤微环境中存在异常炎症成分。免疫检查点抑制剂的开发彻底改变了复发性/转移性头颈部癌症的治疗格局，这些抑制剂是能够抑制免疫抑制信号以引发抗癌免疫的单克隆抗体。然而，头颈部癌症患者对免疫疗法存在原发性耐药。许多正在进行的试验包括免疫疗法与不同治疗干预措施的联合应用，旨在提高反应率和总生存率。随着新型治疗策略的应用，免疫疗法在复发性/转移性头颈部癌症中的重要性不断显现。本综述旨在总结头颈部癌症的联合免疫疗法。
